JZB-34 is under clinical development by Hunan Jingfeng Pharmaceutical and currently in Phase I for Allergic Asthma. According to GlobalData, Phase I drugs for Allergic Asthma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JZB-34’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JZB-34 overview

JZB-34 is under development for the treatment of allergic asthma. It is administered through parenteral route. It is a Fc fusion protein.

Hunan Jingfeng Pharmaceutical overview

Hunan Jingfeng Pharmaceutical, formerly Hunan Tianyi Science and Technology Its products include chemical medicine, biological drug, and traditional Chinese medicine. It provides healthcare services. The company’s main products cover cardiovascular and cerebrovascular diseases, tumors, orthopedics, pediatrics, gynecology, and other major diseases. Th Hunan Jingfeng Pharmaceutical operates through its subsidiaries, which include Hunan Tianyi Aoxing Pump Co., Ltd., Hunan Tianyi Electric Co., Ltd., Hunan Tianyi Cheung Kong Investment Co., Ltd. and Hunan Tianyi Blind Hotel Co., Ltd. Hunan Jingfeng Pharmaceutical is headquartered in Shanghai, China.

For a complete picture of JZB-34’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.